Linagliptina Stada

Linagliptin, the active ingredient in Linagliptina Stada, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It works by enhancing the incretin system, leading to increased insulin secretion and reduced glucagon release, thereby helping to lower blood glucose levels in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance.

Type 2 diabetes mellitus: improves glycaemic control by increasing insulin secretion and decreasing glucagon levels. Adjunct to diet and exercise: used together with lifestyle measures to achieve target HbA1c. Combination therapy with other antidiabetics: may be added to metformin, sulfonylureas, or insulin when monotherapy is insufficient. Patients with renal impairment: can be used without dose adjustment, offering an option for those with decreased kidney function.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Urinary tract infection: dysuria or increased frequency. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, anaphylaxis, or rash. - Hepatic injury: elevated liver enzymes or jaundice. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bullous pemphigoid: blistering skin disorder. - Hypersensitivity syndrome: fever, rash, and organ involvement.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function assessment: evaluate kidney function prior to starting treatment. - Hepatic function monitoring: check liver enzymes periodically during therapy. - Pancreatitis awareness: advise patients to report persistent, severe abdominal pain. - Hypersensitivity vigilance: discontinue if signs of severe allergic reaction appear. - Pregnancy and lactation: use only if potential benefits justify the unknown risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Linagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Diuretics (thiazides): may affect glycaemic control. - ACE inhibitors: monitor blood pressure and renal function.